Tissue Repair Ltd (AU:TRP)
ASX:TRP
Top Page
Tissue Repair Ltd
(Sydney:TRP)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.16
▼(-58.95% Downside)
Action:ReiteratedDate:01/31/26
The score is held back primarily by sustained losses and ongoing negative free cash flow despite accelerating revenue and a debt-free balance sheet. Technicals add further pressure with a strong downtrend (below all major DMAs and negative MACD), while extremely oversold readings provide only modest offset. Valuation is difficult to support because the company is loss-making and has no dividend yield data.
Positive Factors
Accelerating Revenue
A large, sustained revenue step-up signals improving commercial traction and product adoption. Growing top-line provides a broader base to absorb fixed costs, supports scalable growth, and raises the likelihood that future operating leverage can convert sales into durable profit improvements over months.
Negative Factors
Persistent Negative Free Cash Flow
Sustained negative operating and free cash flow creates ongoing runway risk and elevates the probability of future capital raises. Over months, continued cash burn can force dilutive equity issuance or constrain growth investments, impairing long-term return potential for existing shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue
A large, sustained revenue step-up signals improving commercial traction and product adoption. Growing top-line provides a broader base to absorb fixed costs, supports scalable growth, and raises the likelihood that future operating leverage can convert sales into durable profit improvements over months.
Read all positive factors
Tissue Repair Ltd (TRP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$9.67M
Dividend YieldN/A
Average Volume (3M)93.72K
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue Growth178.06%
EPS Growth-2.49%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding60,464,844
10 Day Avg. Volume171,402
30 Day Avg. Volume93,720
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)0.80
Price to Sales (P/S)4.25
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tissue Repair Ltd Business Overview & Revenue Model
Company Description
Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987 and other dressing/matrices, including Gluc...
Tissue Repair Ltd Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
55
Neutral
Cash Flow
28
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.63M | 152.24K | 3.08K | 171.92K | 152.64K |
| Gross Profit | 2.63M | 150.51K | 428.00 | 170.21K | 152.64K |
| EBITDA | -4.72M | -6.51M | -5.14M | -7.01M | -189.44K |
| Net Income | -4.24M | -4.14M | -4.17M | -6.84M | -915.23K |
Balance Sheet | |||||
| Total Assets | 14.57M | 19.39M | 22.38M | 25.90M | 27.61M |
| Cash, Cash Equivalents and Short-Term Investments | 12.32M | 16.44M | 21.40M | 25.46M | 27.11M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 7.50M |
| Total Liabilities | 662.53K | 1.35M | 497.35K | 559.64K | 536.00K |
| Stockholders Equity | 13.91M | 18.04M | 21.88M | 25.34M | 27.07M |
Cash Flow | |||||
| Free Cash Flow | -4.12M | -4.95M | -4.26M | -3.97M | -852.89K |
| Operating Cash Flow | -3.70M | -4.95M | -4.26M | -3.97M | -852.89K |
| Investing Cash Flow | -421.67K | -3.35K | -2.24K | -3.92K | 5.00K |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 21.36M | 7.46M |
Tissue Repair Ltd Technical Analysis
Neutral
0.38
Price Trends
0.17
Negative
0.25
Negative
0.27
Negative
Market Momentum
>-0.01
Negative
45.35
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRP, the sentiment is Neutral. The current price of 0.38 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.17, and above the 200-day MA of 0.27, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.35 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:TRP.
Tissue Repair Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$34.90M | -6.66 | -370.40% | ― | 306.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$9.67M | -2.68 | -29.91% | ― | 178.06% | -2.49% | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
44 Neutral | AU$9.46M | -1.25 | -140.35% | ― | ― | ― | |
42 Neutral | AU$58.88M | -5.28 | -62.49% | ― | ― | 10.78% | |
42 Neutral | AU$9.43M | -1.00 | -218.76% | ― | ― | ― |
* Healthcare Sector Average
AU:TRP
Tissue Repair Ltd
0.16
-0.08
-33.33%
AU:PTX
Prescient Therapeutics Limited
0.06
0.01
33.33%
AU:CMB
Regeneus Ltd.
0.35
0.06
23.21%
AU:AVE
Avecho Biotechnology Limited
0.01
0.00
0.00%
AU:1AD
AdAlta Ltd.
―
―
―
AU:BGT
Bio-Gene Technology Ltd.
0.03
0.00
0.00%
Tissue Repair Ltd Corporate Events
Tissue Repair trims long-dated option pool after conditional rights lapse
Mar 3, 2026
Tissue Repair Ltd has notified the market of the cessation of a total of 416,227 options, comprising two classes of securities that lapsed on 27 February 2026 after the conditions attached to them were not met or became incapable of being satisfie...
Tissue Repair Issues 175,000 Unquoted Options Under Employee Incentive Plan
Feb 27, 2026
Tissue Repair Ltd has issued a total of 175,000 unquoted options under its employee incentive scheme, split between 75,000 options exercisable at $1.15 expiring in March 2039 and 100,000 options exercisable at $0.75 expiring in April 2041. These o...
Tissue Repair Narrows Half-Year Loss as Revenue Jumps but Asset Base Thins
Feb 27, 2026
Tissue Repair Ltd reported a 54.5% increase in revenue to $305,820 for the half-year ended 31 December 2025, while narrowing its loss after tax by 15.1% to $2.17 million compared with the prior corresponding period. The company did not declare any...
Tissue Repair Balances Slower TR987 Trial with Aggressive TR Pro+ Commercial Push
Jan 30, 2026
Tissue Repair reported slower patient randomisation in its US Phase 3 trial of TR987 for chronic wounds, with about 40 patients enrolled so far and a goal of 100 by July 2026 to trigger an interim analysis that will determine whether the late-stag...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.